Skip to main content
Top
Published in: Clinical Rheumatology 1/2011

01-03-2011 | Review

The burden of illness of rheumatoid arthritis

Authors: Annelies Boonen, Johan L. Severens

Published in: Clinical Rheumatology | Special Issue 1/2011

Login to get access

Abstract

It is necessary to understand the full burden of illness of a disease before the value of interventions can be assessed. Rheumatoid arthritis (RA) has an impact on a variety of stakeholders, including patients, healthcare systems, and society as a whole. This overview discusses the societal and patient perspectives, distinguishing several domains of impact. Epidemiology is important from a societal perspective, as it affects the total impact on health and costs related to RA and influences healthcare organization priorities. Co-morbidities, such as cardiovascular disease, are important factors contributing to the impact of RA. The impact on health is, naturally, relevant to both patients and society as a whole, and is summarized by health-related quality-of-life measures from the point of view of the patient and by utilities from the societal perspective. Similarly, work participation is important for both patients and society. Withdrawal from the labor force and short- and long-term sick leave are extensively studied in RA and lead to substantial productivity costs at the societal level and to income loss for patients. In addition, the recent concept of presenteeism, which reflects the problems that patients experience while at work, is considered. Finally, the costs of illness of RA are summarized. Societal costs are mainly driven by the costs of drug treatment and inpatient care, including surgery. Patient and family costs are mainly driven by the need for formal and informal care. Overall, RA has a significant impact on the health of and costs to patients and society, suggesting that effective interventions to reduce the impact are of value.
Literature
1.
go back to reference Gabriel SE, Michaud K (2009) Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 11:229PubMedCrossRef Gabriel SE, Michaud K (2009) Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 11:229PubMedCrossRef
2.
go back to reference Chorus AM, Miedema HS, Boonen A, van der Linden S (2003) Quality of life and work in patients with rheumatoid arthritis and ankylosing spondylitis of working age. Ann Rheum Dis 62:1178–1184PubMedCrossRef Chorus AM, Miedema HS, Boonen A, van der Linden S (2003) Quality of life and work in patients with rheumatoid arthritis and ankylosing spondylitis of working age. Ann Rheum Dis 62:1178–1184PubMedCrossRef
4.
go back to reference Torrance GW (1986) Measurement of health state utilities for economic appraisal. J Health Econ 5:1–30PubMedCrossRef Torrance GW (1986) Measurement of health state utilities for economic appraisal. J Health Econ 5:1–30PubMedCrossRef
5.
go back to reference Bansback N, Harrison M, Brazier J, Davies L, Kopec J, Marra C, Symmons D, Anis A (2008) Health state utility values: a description of their development and application for rheumatic diseases. Arthritis Rheum 59:1018–1026PubMedCrossRef Bansback N, Harrison M, Brazier J, Davies L, Kopec J, Marra C, Symmons D, Anis A (2008) Health state utility values: a description of their development and application for rheumatic diseases. Arthritis Rheum 59:1018–1026PubMedCrossRef
6.
go back to reference Marra CA, Rashidi AA, Guh D, Kopec JA, Abrahamowicz M, Esdaile JM, Brazier JE, Fortin PR, Anis AH (2005) A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med 60:1571–1582PubMedCrossRef Marra CA, Rashidi AA, Guh D, Kopec JA, Abrahamowicz M, Esdaile JM, Brazier JE, Fortin PR, Anis AH (2005) A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med 60:1571–1582PubMedCrossRef
7.
go back to reference Geuskens GA, Burdorf A, Hazes JM (2007) Consequences of rheumatoid arthritis for performance of social roles—a literature review. J Rheumatol 34:1248–1260PubMed Geuskens GA, Burdorf A, Hazes JM (2007) Consequences of rheumatoid arthritis for performance of social roles—a literature review. J Rheumatol 34:1248–1260PubMed
8.
go back to reference Wolfe F, Allaire S, Michaud K (2007) The prevalence and incidence of work disability in rheumatoid arthritis, and the effect of anti-tumor necrosis factor on work disability. J Rheumatol 34:2211–2217PubMed Wolfe F, Allaire S, Michaud K (2007) The prevalence and incidence of work disability in rheumatoid arthritis, and the effect of anti-tumor necrosis factor on work disability. J Rheumatol 34:2211–2217PubMed
9.
go back to reference Verstappen SM, Bijlsma JW, Verkleij H, Buskens E, Blaauw AA, ter Borg EJ, Jacobs JW, Utrecht Rheumatoid Arthritis Cohort Study Group (2004) Overview of work disability in rheumatoid arthritis patients as observed in cross-sectional and longitudinal surveys. Arthritis Rheum 51:488–497PubMedCrossRef Verstappen SM, Bijlsma JW, Verkleij H, Buskens E, Blaauw AA, ter Borg EJ, Jacobs JW, Utrecht Rheumatoid Arthritis Cohort Study Group (2004) Overview of work disability in rheumatoid arthritis patients as observed in cross-sectional and longitudinal surveys. Arthritis Rheum 51:488–497PubMedCrossRef
10.
go back to reference de Croon EM, Sluiter JK, Nijssen TF, Dijkmans BA, Lankhorst GJ, Frings-Dresen MH (2004) Predictive factors of work disability in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 63:1362–1367PubMedCrossRef de Croon EM, Sluiter JK, Nijssen TF, Dijkmans BA, Lankhorst GJ, Frings-Dresen MH (2004) Predictive factors of work disability in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 63:1362–1367PubMedCrossRef
11.
go back to reference Mau W, Listing J, Huscher D, Zeidler H, Zink A (2005) Employment across chronic inflammatory rheumatic diseases and comparison with the general population. J Rheumatol 32:721–728PubMed Mau W, Listing J, Huscher D, Zeidler H, Zink A (2005) Employment across chronic inflammatory rheumatic diseases and comparison with the general population. J Rheumatol 32:721–728PubMed
12.
go back to reference Chung CP, Sokka T, Arbogast PG, Pincus T (2006) Work disability in early rheumatoid arthritis: higher rates but better clinical status in Finland compared with the US. Ann Rheum Dis 65:1653–1657PubMedCrossRef Chung CP, Sokka T, Arbogast PG, Pincus T (2006) Work disability in early rheumatoid arthritis: higher rates but better clinical status in Finland compared with the US. Ann Rheum Dis 65:1653–1657PubMedCrossRef
13.
go back to reference de Buck PD, de Bock GH, van Dijk F, van den Hout WB, Vandenbroucke JP, Vliet Vlieland TP (2006) Sick leave as a predictor of job loss in patients with chronic arthritis. Int Arch Occup Environ Health 80:160–170PubMedCrossRef de Buck PD, de Bock GH, van Dijk F, van den Hout WB, Vandenbroucke JP, Vliet Vlieland TP (2006) Sick leave as a predictor of job loss in patients with chronic arthritis. Int Arch Occup Environ Health 80:160–170PubMedCrossRef
14.
go back to reference Björk M, Thyberg I, Rikner K, Balogh I, Gerdle B (2009) Sick leave before and after diagnosis of rheumatoid arthritis—a report from the Swedish TIRA Project. J Rheumatol 36:1170–1179PubMedCrossRef Björk M, Thyberg I, Rikner K, Balogh I, Gerdle B (2009) Sick leave before and after diagnosis of rheumatoid arthritis—a report from the Swedish TIRA Project. J Rheumatol 36:1170–1179PubMedCrossRef
15.
go back to reference Walker N, Michaud K, Wolfe F (2005) Work limitations among working persons with rheumatoid arthritis: results, reliability, and validity of the work limitations questionnaire in 836 patients. J Rheumatol 32:1006–1012PubMed Walker N, Michaud K, Wolfe F (2005) Work limitations among working persons with rheumatoid arthritis: results, reliability, and validity of the work limitations questionnaire in 836 patients. J Rheumatol 32:1006–1012PubMed
16.
go back to reference Zhang W, Bansback N, Guh D, Li X, Nosyk B, Marra CA, Anis AH (2008) Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis. J Rheumatol 35:1729–1736PubMed Zhang W, Bansback N, Guh D, Li X, Nosyk B, Marra CA, Anis AH (2008) Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis. J Rheumatol 35:1729–1736PubMed
17.
go back to reference Gilworth G, Chamberlain MA, Harvey A, Woodhouse A, Smith J, Smyth MG, Tennant A (2003) Development of a work instability scale for rheumatoid arthritis. Arthritis Rheum 49:349–354PubMedCrossRef Gilworth G, Chamberlain MA, Harvey A, Woodhouse A, Smith J, Smyth MG, Tennant A (2003) Development of a work instability scale for rheumatoid arthritis. Arthritis Rheum 49:349–354PubMedCrossRef
18.
go back to reference Gilworth G, Emery P, Gossec L, Vliet Vlieland TP, Breedveld FC, Hueber AJ, Schett G, Tennant A (2008) Adaptation and cross-cultural validation of the RA-WIS (Work Instability Scale). Ann Rheum Dis. doi:10.1136/ard.2008.098921 PubMed Gilworth G, Emery P, Gossec L, Vliet Vlieland TP, Breedveld FC, Hueber AJ, Schett G, Tennant A (2008) Adaptation and cross-cultural validation of the RA-WIS (Work Instability Scale). Ann Rheum Dis. doi:10.​1136/​ard.​2008.​098921 PubMed
19.
go back to reference Verstappen SM, Hoes JN, Ter Borg EJ, Bijlsma JW, Blaauw AA, van Albada-Kuipers GA, van Booma-Frankfort C, Jacobs JW (2006) Joint surgery in the Utrecht Rheumatoid Arthritis Cohort: the effect of treatment strategy. Ann Rheum Dis 65:1506–1511PubMedCrossRef Verstappen SM, Hoes JN, Ter Borg EJ, Bijlsma JW, Blaauw AA, van Albada-Kuipers GA, van Booma-Frankfort C, Jacobs JW (2006) Joint surgery in the Utrecht Rheumatoid Arthritis Cohort: the effect of treatment strategy. Ann Rheum Dis 65:1506–1511PubMedCrossRef
21.
go back to reference Jacob-Tacken KHM, Koopmanschap MA, Meerding WJ, Severens JL (2005) Correcting for compensating mechanisms related to productivity costs in economic evaluations of health care programmes. Health Econ 23:47–54 Jacob-Tacken KHM, Koopmanschap MA, Meerding WJ, Severens JL (2005) Correcting for compensating mechanisms related to productivity costs in economic evaluations of health care programmes. Health Econ 23:47–54
22.
go back to reference Wolfe F, Michaud K, Choi HK, Williams R (2005) Household income and earnings losses among 6, 396 persons with rheumatoid arthritis. J Rheumatol 32:1875–1883PubMed Wolfe F, Michaud K, Choi HK, Williams R (2005) Household income and earnings losses among 6, 396 persons with rheumatoid arthritis. J Rheumatol 32:1875–1883PubMed
23.
go back to reference Westhovens R, Boonen A, Verbruggen L, Durez P, De Clerck L, Malaise M, Mielants H (2005) Healthcare consumption and direct costs of rheumatoid arthritis in Belgium. Clin Rheumatol 24:615–619PubMedCrossRef Westhovens R, Boonen A, Verbruggen L, Durez P, De Clerck L, Malaise M, Mielants H (2005) Healthcare consumption and direct costs of rheumatoid arthritis in Belgium. Clin Rheumatol 24:615–619PubMedCrossRef
24.
go back to reference Lapsley HM, March LM, Tribe KL, Cross MJ, Courtenay BG, Brooks PM, Arthritis Cost and Outcome Project Group (2002) Living with rheumatoid arthritis: expenditures, health status, and social impact on patients. Ann Rheum Dis 61:818–821PubMedCrossRef Lapsley HM, March LM, Tribe KL, Cross MJ, Courtenay BG, Brooks PM, Arthritis Cost and Outcome Project Group (2002) Living with rheumatoid arthritis: expenditures, health status, and social impact on patients. Ann Rheum Dis 61:818–821PubMedCrossRef
25.
go back to reference Curkendall S, Patel V, Gleeson M, Campbell RS, Zagari M, Dubois R (2008) Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter? Arthritis Rheum 59:1519–1526PubMedCrossRef Curkendall S, Patel V, Gleeson M, Campbell RS, Zagari M, Dubois R (2008) Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter? Arthritis Rheum 59:1519–1526PubMedCrossRef
Metadata
Title
The burden of illness of rheumatoid arthritis
Authors
Annelies Boonen
Johan L. Severens
Publication date
01-03-2011
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue Special Issue 1/2011
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-010-1634-9

Other articles of this Special Issue 1/2011

Clinical Rheumatology 1/2011 Go to the issue

Introduction

Introduction

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.